1
|
Continisio S, Montonati C, Angelini F, Bocchino PP, Carbonaro C, Giacobbe F, Dusi V, De Filippo O, Ielasi A, Giannino G, Boldi E, Fabris T, D'Ascenzo F, De Ferrari GM, Tarantini G. Single versus dual antiplatelet therapy following percutaneous left atrial appendage closure-A systematic review and meta-analysis. Eur J Clin Invest 2024:e14209. [PMID: 38597271 DOI: 10.1111/eci.14209] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 01/02/2024] [Revised: 03/08/2024] [Accepted: 03/16/2024] [Indexed: 04/11/2024]
Abstract
BACKGROUND In the last few years, percutaneous LAA occlusion (LAAO) has become a plausible alternative in atrial fibrillation (AF) patients with contraindications to anticoagulation therapy. Nevertheless, the optimal antiplatelet strategy following percutaneous LAAO remains to be defined. METHODS Studies comparing single antiplatelet therapy (SAPT) versus dual antiplatelet therapy (DAPT) following LAAO were systematically searched and screened. The outcomes of interest were ischemic stroke, device-related thrombus (DRT) and major bleeding. A random-effect meta-analysis was performed comparing outcomes in both groups. The moderator effect of baseline characteristics on outcomes was evaluated by univariate meta-regression analyses. RESULTS Sixteen observational studies with 3255 patients treated with antiplatelet therapy (SAPT, n = 1033; DAPT, n = 2222) after LAAO were included. Mean age was 74.5 ± 8.3 years, mean CHA2DS2-VASc and HAS-BLED scores were 4.3 ± 1.5 and 3.2 ± 1.0, respectively. At a weighted mean follow-up of 12.7 months, the occurrence of stroke (RR 1.33; 95% CI 0.64-2.77; p =.44), DRT (RR 1.52; 95% CI 0.90-2.58; p =.12), and the composite of stroke and DRT (RR 1.26; 95% CI 0.67-2.37; p =.47) did not differ significantly between SAPT and DAPT groups. The rate of major bleedings was also not different between groups (RR 1.41; 95% CI 0.64-3.12; p =.39). CONCLUSIONS Among AF patients at high bleeding risk undergoing percutaneous LAAO, a post-procedural minimalistic antiplatelet strategy with SAPT did not significantly differ from DAPT regimens regarding the rate of stroke, DRT and major bleeding.
Collapse
Affiliation(s)
- Saverio Continisio
- Division of Cardiology, Clinica S. Rocco di Franciacorta, Brescia, Italy
| | - Carolina Montonati
- Division of Cardiology, IRCCS Hospital Galeazzi-Sant'Ambrogio, Milan, Italy
| | - Filippo Angelini
- Division of Cardiology, Cardiovascular and Thoracic Department, 'Città della Salute e della Scienza' Hospital, Turin, Italy
| | - Pier Paolo Bocchino
- Division of Cardiology, Cardiovascular and Thoracic Department, 'Città della Salute e della Scienza' Hospital, Turin, Italy
| | - Carla Carbonaro
- Department of Medical Sciences, University of Turin, Turin, Italy
| | | | - Veronica Dusi
- Division of Cardiology, Cardiovascular and Thoracic Department, 'Città della Salute e della Scienza' Hospital, Turin, Italy
- Department of Medical Sciences, University of Turin, Turin, Italy
| | - Ovidio De Filippo
- Division of Cardiology, Cardiovascular and Thoracic Department, 'Città della Salute e della Scienza' Hospital, Turin, Italy
| | - Alfonso Ielasi
- Division of Cardiology, IRCCS Hospital Galeazzi-Sant'Ambrogio, Milan, Italy
| | | | - Emiliano Boldi
- Division of Cardiology, Clinica S. Rocco di Franciacorta, Brescia, Italy
| | - Tommaso Fabris
- Department of Cardiac, Thoracic, Vascular Sciences and Public Health, University of Padua Medical School, Padua, Italy
| | - Fabrizio D'Ascenzo
- Division of Cardiology, Cardiovascular and Thoracic Department, 'Città della Salute e della Scienza' Hospital, Turin, Italy
- Department of Medical Sciences, University of Turin, Turin, Italy
| | - Gaetano Maria De Ferrari
- Division of Cardiology, Cardiovascular and Thoracic Department, 'Città della Salute e della Scienza' Hospital, Turin, Italy
- Department of Medical Sciences, University of Turin, Turin, Italy
| | - Giuseppe Tarantini
- Department of Cardiac, Thoracic, Vascular Sciences and Public Health, University of Padua Medical School, Padua, Italy
| |
Collapse
|
2
|
Lanzone AM, Castelluccio EV, Della Pina P, Boldi E, Lussardi G, Frati G, Gaudio C, Biondi-Zoccai G. Comparative diagnostic accuracy of transcranial Doppler and contrast-enhanced transthoracic echocardiography for the diagnosis of patent foramen ovale and atrial septal defect. Panminerva Med 2024:S0031-0808.24.05123-1. [PMID: 38563605 DOI: 10.23736/s0031-0808.24.05123-1] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 04/04/2024]
Abstract
BACKGROUND Recognition of right-to-left shunt is crucial in the work-up of patients with suspected patent foramen ovale (PFO) or atrial septal defect (ASD). While transesophageal echocardiography (TEE) remains the gold standard diagnostic tool for the anatomic assessment of PFO/ASD, transcranial Doppler (TCD) and contrast-enhanced transthoracic echocardiogram (CE-TTE) hold the promise of providing minimally invasive yet accurate clinical details. Their comparative accuracy remains however debated. METHODS We conducted a retrospective observational study leveraging our extensive institutional experience with systematic TCD and CE-TTE in patients with suspected PFO/ASD. Several measures of diagnostic test accuracy were computed, with point estimates and 95% confidence intervals, when applicable. RESULTS A total of 1358 patients were included, with age 48±14 years and 772 (58%) women. Tests were performed for diagnostic purposes in 797 (58.6%) and during follow-up in 740 (54.5%). A PFO was eventually diagnosed in 1038 (77.9%) patients, and an ASD in 60 (4.5%). Agreement between TCD and CE-TTE occurred in 1309 (85.2%) cases, with TCD yielding worse findings than CE-TTE in 91 (5.9%) patients, and vice versa in 137 (8.9%), yielding a Cohen kappa of 78.6% (95% CI: 76.3-81.1%) and a highly significant P value at McNemar test (P<0.001). After dichotomization, and using TCD as benchmark, CE-TTE yielded sensitivity 96.9%, specificity 95.1%, area under the curve 92.1%, and P=0.249. Similar findings were obtained when focusing only on diagnostic tests or follow-up ones (Cohen kappa respectively 74.0% [70.2-77.1%], P<0.001 and 80.3% [76.4-84.3%], P<0.001). Notably, Valsalva was necessary to disclose the presence of shunt during TCD in 487 (31.7%) patients and during CE-TTE in 482 (31.4%) cases. Finally, performance of TCD and CE-TTE in a subset of patients eventually undergoing TTE was quite similar. CONCLUSIONS The diagnostic accuracy of CE-TTE appears favorable, and this imaging test may identify patients who may be missed if only TCD is used to screen patients with suspected PFO/ASD. Accordingly, CE-TTE is recommended as an adjunct diagnostic modality for all patients with a high pre-test probability of PFO/ASD and right-to-left shunt.
Collapse
Affiliation(s)
- Alberto M Lanzone
- Division of Cardiology and Coronary Care Unit, San Rocco Clinical Institute, Ome, Brescia, Italy
| | - Emanuele V Castelluccio
- Department of Health Promotion, Mother and Child Care, G. D'Alessandro Internal Medicine and Medical Specialties (PROMISE), University of Palermo, Palermo, Italy
- Division of Cardiology, Paolo Giaccone University Hospital, Palermo, Italy
| | - Paolo Della Pina
- Division of Cardiology and Coronary Care Unit, San Rocco Clinical Institute, Ome, Brescia, Italy
| | - Emiliano Boldi
- Division of Cardiology and Coronary Care Unit, San Rocco Clinical Institute, Ome, Brescia, Italy
| | | | - Giacomo Frati
- Department of Medical-Surgical Sciences and Biotechnologies, Sapienza University, Latina, Italy
- IRCCS Neuromed, Pozzilli, Isernia, Italy
| | - Carlo Gaudio
- Department of Clinical, Internal Medicine, Anesthesiological and Cardiovascular Sciences, Sapienza University, Rome, Italy
| | - Giuseppe Biondi-Zoccai
- Department of Medical-Surgical Sciences and Biotechnologies, Sapienza University, Latina, Italy -
- Mediterranea Cardiocentro, Naples, Italy
| |
Collapse
|
3
|
Lanzone AM, Albiero R, Boldi E, Safari D, Serafin P, Lussardi G, Rigamonti ER, Anselmi A. Clinical and echocardiographic outcomes after percutaneous closure of patent foramen ovale: a single center experience. Minerva Cardiol Angiol 2023; 71:157-164. [PMID: 33703865 DOI: 10.23736/s2724-5683.21.05609-x] [Citation(s) in RCA: 3] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/08/2022]
Abstract
BACKGROUND Patent foramen ovale (PFO) has a high estimated prevalence (25% of the general population) and has been implicated in the pathogenesis of cryptogenic stroke and transient ischemic attack (TIA), as well as in the pathogenesis of migraine headache. This study evaluated the effectiveness of percutaneous transcatheter PFO closure with Amplatzer™ (Abbott Laboratories, Abbott Park, IL, USA) devices, from a large single-center experience. METHODS From January 1998 to December 2014, 577 patients (243 males and 334 females, mean age 50 years, range 11-82 years) with documented PFO and history of at least one episode of cryptogenic stroke/TIA (N.=356) or occasional finding of previous ischemic lesions on MRI (N.=221) underwent percutaneous transcatheter closure of PFO using an Amplatzer™ Occluder (Abbott Laboratories). All the procedures were performed under general anesthesia or mild sedation and were assisted by transesophageal or intracardiac echocardiography. RESULTS Procedural success was 100%. After a median follow-up period of 2.7 years with echocardiographic evaluations, the rate of recurrent adverse cerebral events was 0.4%. Two patients (0.4%) required a secondary procedure for significant residual shunt. Of 36 patients with minor residual shunt, 30 (83%) showed spontaneous shunt regression at follow-up. There was a consistent decrease after procedure in headache migraine, platypnea-orthodeoxia, fainting episodes, syncope, and coenesthesia phenomena. CONCLUSIONS Transcatheter PFO closure is an effective and safe therapy for the prevention of thromboembolic events in the patients with cryptogenic stroke/TIA or an occasional finding of a positive cerebral MRI. Late follow-up shows device stability and clinical improvement in the majority of patients.
Collapse
Affiliation(s)
- Alberto M Lanzone
- Department of Cardiology, Cath Lab Service, Cardio-Neurological Center, San Rocco Clinical Institute, Ome, Brescia, Italy
| | - Remo Albiero
- Department of Cardiology, Cath Lab Service, Cardio-Neurological Center, San Rocco Clinical Institute, Ome, Brescia, Italy
| | - Emiliano Boldi
- Department of Cardiology, Cath Lab Service, Cardio-Neurological Center, San Rocco Clinical Institute, Ome, Brescia, Italy
| | - Davood Safari
- Department of Cardiology, Cath Lab Service, Cardio-Neurological Center, San Rocco Clinical Institute, Ome, Brescia, Italy
| | - Paolo Serafin
- Department of Cardiology, Cath Lab Service, Cardio-Neurological Center, San Rocco Clinical Institute, Ome, Brescia, Italy
| | - Gianluca Lussardi
- Department of Cardiology, Cath Lab Service, Cardio-Neurological Center, San Rocco Clinical Institute, Ome, Brescia, Italy
| | - Elia R Rigamonti
- Department of Internal Medicine, Ente Ospedaliero Cantonale, Lugano, Switzerland
| | - Amedeo Anselmi
- Division of Thoracic and Cardiovascular Surgery, Pontchaillou University Hospital, Rennes, France -
| |
Collapse
|
4
|
Musuraca G, Agostoni P, Boldi E, Imperadore F, Terraneo C, Broso GP. Very late migration to and retrieval of an Amplatzer patent foramen ovale occlusion device from the abdominal aortic carrefour. J Cardiovasc Med (Hagerstown) 2018; 19:459-461. [PMID: 29894354 DOI: 10.2459/jcm.0000000000000674] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/05/2022]
Affiliation(s)
- Gerardo Musuraca
- Division of Cardiology, S. Maria del Carmine Hospital, Rovereto, Italy
| | | | - Emiliano Boldi
- Division of Cardiology, Clinica S. Rocco di Franciacorta, Ome
| | | | | | - Giovanni P Broso
- Division of Cardiology, S. Maria del Carmine Hospital, Rovereto, Italy
| |
Collapse
|
5
|
Musuraca G, Agostoni P, Terraneo C, Boldi E, Di Matteo I, Centonze M. Coronarographyc detection of double right coronary artery arising from two separated ostia in the right sinus of Valsalva. Minerva Cardioangiol 2015; 63:589-590. [PMID: 26373779] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 06/05/2023]
Affiliation(s)
- G Musuraca
- Division of Cardiology, S. Maria del Carmine Hospital, Rovereto, Italy -
| | | | | | | | | | | |
Collapse
|
6
|
Metra M, Nodari S, Boldi E, Bontempi L, Chizzola G, Bordonali T, Vizzardi E, Cas LD. Different responses to inotropic agents after long term β-blockade with either metoprolol or carvedilol in patients with chronic heart failure. Eur J Heart Fail 2004. [DOI: 10.1016/s1388-9842(00)80202-0] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 10/27/2022] Open
Affiliation(s)
- M. Metra
- Chair of Cardiology; University of Brescia; Italy
| | - S. Nodari
- Chair of Cardiology; University of Brescia; Italy
| | - E. Boldi
- Chair of Cardiology; University of Brescia; Italy
| | - L. Bontempi
- Chair of Cardiology; University of Brescia; Italy
| | - G. Chizzola
- Chair of Cardiology; University of Brescia; Italy
| | - T. Bordonali
- Chair of Cardiology; University of Brescia; Italy
| | - E. Vizzardi
- Chair of Cardiology; University of Brescia; Italy
| | - L. Dei Cas
- Chair of Cardiology; University of Brescia; Italy
| |
Collapse
|
7
|
Mascioli G, Curnis A, Boldi E, Bontempi L, Dei Cas L. Comparison in terms of handling and performances between two new leads for left ventricular pacing through coronary sinus: Medtronic 4191 (SW) and guidant easy-track (OW). Europace 2001. [DOI: 10.1016/eupace/2.supplement_1.a35] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/17/2022] Open
|
8
|
Mascioli G, Cumis A, Boldi E, Metra M, Bontempi L, Dei Cas L. Dislodgment of the lead in coronary sinus for left ventricular pacing: Is this event predictable on the basis of any parameters evaluable at implant? Europace 2001. [DOI: 10.1016/eupace/2.supplement_1.a32-b] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/27/2022] Open
|
9
|
Metra M, Giubbini R, Nodari S, Boldi E, Modena MG, Dei Cas L. Differential effects of beta-blockers in patients with heart failure: A prospective, randomized, double-blind comparison of the long-term effects of metoprolol versus carvedilol. Circulation 2000; 102:546-51. [PMID: 10920067 DOI: 10.1161/01.cir.102.5.546] [Citation(s) in RCA: 242] [Impact Index Per Article: 10.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
BACKGROUND Both metoprolol and carvedilol produce hemodynamic and clinical benefits in patients with chronic heart failure; carvedilol exerts greater antiadrenergic effects than metoprolol, but it is unknown whether this pharmacological difference results in hemodynamic and clinical differences between the 2 drugs. METHODS AND RESULTS We randomized 150 patients with heart failure (left ventricular ejection fraction </=0.35) to double-blind treatment with either metoprolol or carvedilol. When compared with metoprolol (124+/-55 mg/d), patients treated with carvedilol (49+/-18 mg/d) showed larger increases in left ventricular ejection fraction at rest (+10.9+/-11.0 versus +7.2+/-7.7 U, P=0.038) and in left ventricular stroke volume and stroke work during exercise (both P<0. 05) after 13 to 15 months of treatment. In addition, carvedilol produced greater decreases in mean pulmonary artery pressure and pulmonary wedge pressure, both at rest and during exercise, than metoprolol (all P<0.05). In contrast, the metoprolol group showed greater increases in maximal exercise capacity than the carvedilol group (P=0.035), but the 2 drugs improved symptoms, submaximal exercise tolerance, and quality of life to a similar degree. After a mean of 23+/-11 months of follow-up, 21 patients in the metoprolol group and 17 patients in the carvedilol group died or underwent urgent transplantation. CONCLUSIONS The present study demonstrates that during long-term therapy, carvedilol improves cardiac performance to a greater extent than metoprolol when administered to patients with heart failure in the doses shown to be effective in clinical trials. These differences were likely related to a greater antiadrenergic activity of carvedilol.
Collapse
Affiliation(s)
- M Metra
- Cattedra di Cardiologia, Università di Brescia, Italy.
| | | | | | | | | | | |
Collapse
|
10
|
Metra M, Nodari S, Boldi E, Chizzola G, Bordonali T, Vizzardi E, Vigliani F, Cas LD. Near normalization of left ventricular function after long-term β-blockade in patients with heart failure: Clinical characteristics and prognostic meaning. Eur J Heart Fail 2000. [DOI: 10.1016/s1388-9842(00)80201-9] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 10/27/2022] Open
Affiliation(s)
- M. Metra
- Chair of Cardiology; University of Brescia; Italy
| | - S. Nodari
- Chair of Cardiology; University of Brescia; Italy
| | - E. Boldi
- Chair of Cardiology; University of Brescia; Italy
| | - G. Chizzola
- Chair of Cardiology; University of Brescia; Italy
| | - T. Bordonali
- Chair of Cardiology; University of Brescia; Italy
| | - E. Vizzardi
- Chair of Cardiology; University of Brescia; Italy
| | - F. Vigliani
- Chair of Cardiology; University of Brescia; Italy
| | - L. Dei Cas
- Chair of Cardiology; University of Brescia; Italy
| |
Collapse
|
11
|
Abstract
Controlled clinical trials, performed in more than 13,000 patients, have consistently shown the beneficial effects of long-term beta-blocker therapy in patients with chronic heart failure. However, it is not clear whether this is a class effect or if it is specific only for some agents. Beneficial effects on the prognosis of the patients with mild to moderate heart failure have been obtained with metoprolol, bisoprolol, and carvedilol. Metoprolol and bisoprolol are selective for beta(1)-receptors and without ancillary properties, carvedilol, at doses of 25 mg twice daily, blocks beta(1)-, beta(2)-, and a(1)-adrenergic receptors, and has associated antiproliferative and antioxidant activities. These differences are important for the acute hemodynamic effects, but it is still controversial whether they may also influence the long-term effects of therapy. Differently from selective b-blockers, carvedilol blocks all adrenergic receptors, does not upregulate beta1-receptors, decreases cardiac norepinephrine release, and has associated antioxidant effects. These differences may cause a larger increase in left ventricular function, which was significant in some, but not all of the direct comparisons of the two agents. The long-term effects of different beta-blockers on prognosis are currently compared in the Carvedilol or Metoprolol European Trial, in which more than 3000 patients with chronic heart failure have been 1:1 randomized to metoprolol or carvedilol and are going to be followed for more than 2 years.
Collapse
Affiliation(s)
- M Metra
- Cattedra di Cardiologia, Università di Brescia, c/o Spedali Civili Piazza Spedali Civili, 25100 Brescia, Italy
| | | | | | | |
Collapse
|
12
|
Abstract
BACKGROUND Cardiac sympathetic activation is one of the major and earlier changes observed in patients with heart failure. Its relation to the severity of the disease and its independent prognostic value show that it may directly contribute to the progression of heart failure. beta-Blockers are the most effective tool to counteract the untoward effects of sympathetic activation on the cardiovascular system. METHODS AND RESULTS We reviewed the results of the placebo-controlled, double-blind studies about the effects of beta-blockers in patients with heart failure. These studies have involved almost 10,000 patients to date and have consistently shown that the long-term administration of beta-blockers is associated with a highly significant improvement in both left ventricular function and prognosis of the patients with heart failure. The evidence supporting the use of beta-blockers now equals or even surpasses that of angiotensin-converting enzyme inhibitors; therefore beta-blockers should be considered part of standard therapy. Issues that remain unclarified include the mechanisms through which beta-blockers may improve cardiac function and their tolerability and efficacy in specific groups of patients (such as those with asymptomatic left ventricular dysfunction, severe heart failure, the elderly, or those with left ventricular diastolic dysfunction). It is not currently clear whether the pharmacologic differences between individual beta-blockers are clinically relevant. If they are, the potential for even greater benefit with certain agents exists. It is hoped that these issues will be clarified by the results of ongoing multicenter trials.
Collapse
Affiliation(s)
- M Metra
- Cattedra di Cardiologia, Università di Brescia, Brescia, Italy.
| | | | | | | | | | | |
Collapse
|
13
|
Metra M, Nodari S, Bordonali T, Cagnazzi E, Boldi E, Dei Cas L. [ACE-inhibitors, AT1 receptor antagonists and diastolic dysfunction]. Cardiologia 1999; 44 Suppl 1:53-8. [PMID: 12497882] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 02/28/2023]
Affiliation(s)
- M Metra
- Cattedra di Cardiologia, Università degli Studi, Spedali Civili Piazzale Spedali Civili, 1, 25123 Brescia
| | | | | | | | | | | |
Collapse
|
14
|
Abstract
Although reduced exercise capacity is the main complaint of patients with congestive heart failure (CHF), the best method to measure it remains controversial. Peak VO2, obtained using maximal exercise testing, is the most accurate measure of maximal functional capacity. It is related to peak exercise cardiac output and is one of the most important independent variables for the prognostic assessment of patients with CHF. It has, however, a low sensitivity for measurement of changes induced by therapy and is poorly related to everyday physical activity, patient symptoms, and quality of life. The anerobic threshold may also be regarded as a parameter of maximal functional capacity. Its value is mainly indirect, because it shows that the patient is performing a maximal effort limited by the cardiovascular system. The VO2 kinetics at the start and at the end of exercise are probably more related to patient symptoms, but it is unresolved which protocols and parameters might best be used to study this aspect of exercise performance. Duration of a submaximal exercise at a constant work rate and the distance walked during a 6-min walking test are gaining wide popularity as parameters of submaximal performance. However, when these exams are carried out up to exhaustion in patients with severe functional limitation, they may involve attainment of the anerobic threshold and therefore their clinical meaning may be similar to the one of a maximal exercise test. Moreover, tests based on the assessment of submaximal exercise capacity have been useful for assessment of therapy in single-center trials but have been often inadequate in multicenter trials.
Collapse
Affiliation(s)
- M Metra
- Department of Cardiology, University of Brescia, Italy
| | | | | | | | | | | | | | | |
Collapse
|
15
|
Zanini R, Curello S, Bonandi L, Giovannini G, Boldi E, D'Aloia A, Metra M, Nodari S, Dei Cas L. [Etiopathogenesis of acute myocardial infarction: role of early leukocytosis]. Cardiologia 1998; 43:925-31. [PMID: 9859607] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 02/09/2023]
Abstract
It has recently been suggested that inflammation may play an important role in the pathogenesis of acute ischemic syndromes. It may therefore be important to relate their clinical features with plasma indexes of inflammation. We have studied leukocyte, platelet and fibrinogen blood levels in 57 consecutive patients with acute myocardial infarction admitted to our Intensive Care Unit within 90 min after the onset of chest pain and treated with primary coronary angioplasty. Patients were divided into two groups on the basis of blood leukocyte levels: Group A, 24 patients, 17 males, mean age 54.2 +/- 13.7 years, with high blood leukocytes and Group B, 33 patients, 28 males, mean age 60.9 +/- 10.3 years, with normal blood leukocytes. Group A patients also had higher serum fibrinogen (p = 0.05) and blood platelet levels (p < 0.05). The stenosis observed after guidewire advancement was significant (> 75%) in 33% of the patients with leukocytosis vs 94% of the others (p < 0.01). No difference between the two groups was observed in the success rate of coronary angioplasty and prevalence of stent placement (100 vs 97%, and 43 vs 42% of the patients of Group A and B, respectively). In contrast, a tendency to rethrombosis requiring Rheopro administration was observed in 62% Group A patients vs 21% Group B patients (p < 0.01). In conclusion, the finding of leukocytosis in the acute phase of myocardial infarction suggests that coronary occlusion is mainly caused by a coronary thrombus occurring at the site of a non significant stenosis. In contrast, when blood leukocytes are normal, the underlying coronary stenosis is more often critical and the thrombotic process is less important. The high blood leukocytes, platelet and fibrinogen levels of Group A patients are consistent with a significant role of inflammation in the pathogenesis of the thrombotic process while hemodynamic and local mechanical factors are probably more important in patients with normal blood leukocytes.
Collapse
Affiliation(s)
- R Zanini
- Cattedra e Divisione di Cardiologia, Università degli Studi, Brescia
| | | | | | | | | | | | | | | | | |
Collapse
|
16
|
Metra M, Nodari S, Garbellini M, Boldi E, Rosselli F, Milan E, Giubbini R, Dei Cas L. [The effects of mid- and long-term administration (3-4 years) of carvedilol in patients with idiopathic dilated cardiomyopathy]. Cardiologia 1997; 42:503-12. [PMID: 9289367] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 02/05/2023]
Abstract
Carvedilol has been shown to determine a significant improvement in left ventricular function, symptoms, clinical course and prognosis of patients with chronic heart failure. However, these results were obtained in medium-term studies of < 1 year duration. We report the results obtained with long-term (3-4 years) carvedilol administration to 40 patients with idiopathic dilated cardiomyopathy who were initially recruited in a 4-month double-blind placebo-controlled trial. In the initial 4-month double-blind trial, 20 patients were randomized to placebo and 20 to carvedilol treatment. All patients, except one who was not on ACE-inhibitors, were on digoxin, furosemide and ACE-inhibitors. Carvedilol or placebo doses were progressively titrated, at weekly intervals, up to the maximal doses of 25 mg bid. After the initial 4-month double-blind phase, all patients were followed long term. Mean follow-up duration was 52 +/- 12 months (range 48-61). Among the 20 patients initially randomized to carvedilol administration, 4 died (3 for cardiac and 1 for extracardiac causes) and 2 underwent heart transplant. Among the 20 patients initially randomized to placebo, 5 died for cardiac causes, 3 underwent heart transplant and 4 were started on carvedilol because of progressive heart failure during the initial 4 months of the study. The remaining 8 patients, who were kept on digoxin, furosemide and ACE-inhibitors, were used as control group. Each patient underwent an assessment of clinical conditions (NYHA functional classification and Minnesota Living with Heart Failure questionnaire), equilibrium radionuclide ventriculography, and maximal cardiopulmonary bicycle exercise testing. Exams were performed before treatment, after 4 and 12 months, and at the end of the follow-up period. No significant difference between the carvedilol and control group was present at baseline. Compared with baseline, patients in the control group presented a significant increase in left ventricular end-diastolic volume after long-term follow-up (from 126 +/- 62 to 138 +/- 43 and 158 +/- 52 ml/m2 after 12 and 48 months, respectively). No significant difference, compared to baseline values, was noted. Patients on carvedilol presented a persistent improvement in left ventricular function. This was shown by the progressive increment in left ventricular ejection fraction from 22 +/- 6 to 34 +/- 11, 37 +/- 11 and 37 +/- 13%, after 4, 12 and 48 months, respectively (p < 0.001) with a concomitant reduction in left ventricular end-diastolic volume from 147 +/- 54 to 101 +/- 44 ml/m2 at the end of the follow-up (p < 0.05). NYHA functional class remained significantly improved, in comparison with baseline (2.6 +/- 0.5 to 1.9 +/- 0.3, 1.9 +/- 0.8 and 2.0 +/- 1.0 after 4, 12 and 48 months, respectively; p < 0.01). Maximal functional capacity, assessed as peak VO2 was not significantly changed after 4 months (from 15.2 +/- 3.6 to 16.4 +/- 4.0 ml/kg/min) and showed a tendency towards a further improvement after 12 months and at the end of the follow-up (17.3 +/- 5.6 and 17.2 +/- 5.3 ml/kg/min, respectively). These results show that the favorable effects of carvedilol administration on left ventricular function and clinical symptoms are maintained also after long-term treatment.
Collapse
Affiliation(s)
- M Metra
- Cattedra di Cardiologia, Università degli Studi, Brescia
| | | | | | | | | | | | | | | |
Collapse
|